Navigation Links
EGFR-targeting antibody licensed to Abbott
Date:11/17/2008

The international Ludwig Institute for Cancer Research (LICR) announced today that one of its spin-off companies, Life Science Pharmaceuticals, has licensed its lead cancer therapy candidate, antibody 806, to pharmaceutical company Abbott.

The 806 antibody targets the EGFR cell surface protein but crucially only when the protein is over-expressed (over-produced) in cancer. Overexpression of EGFR occurs in more than 50% of some types of cancers. Current therapies that target EGFR, such as Tarceva and Erbitux, cause side-effects by targeting EGFR both when it is overexpressed on cancer cells and when it is present in usual amounts on normal cells.

According to Prof. Andrew M. Scott, Director of the LICR Melbourne Centre, the ability of the 806 antibody to distinguish between normal EGFR and over-expressed EGFR made it the first example of a second-generation of targeting antibodies. "Our phase I clinical trial showed very clearly that the 806 antibody exquisitely targets a variety of tumours, including brain, lung, head and neck, skin and colorectal cancers. Most importantly, we demonstrated that the antibody does not bind to any normal tissues or cause any significant toxicity. This suggests the 806 antibody will have anti-tumour effects without the side effects commonly seen following treatment with other EGFR-targeting therapies."

The 806 antibody was generated in the laboratory of Dr. Lloyd J. Old, Director of the LICR New York Branch, to bind specifically to a mutant EGFR found in glioblastoma, a particular type of brain tumour. However, detailed characterization by the Institute's branches in Melbourne, New York and San Diego showed that the 806 antibody binds also to normal EGFR only when it is over-expressed, such as on cancer cells.


'/>"/>

Contact: Sarah L. White
swhite@licr.org
212-450-1543
Ludwig Institute for Cancer Research
Source:Eurekalert

Page: 1

Related medicine news :

1. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
2. Antibody leads to repair of myelin sheath in lab study of multiple sclerosis and related disorders
3. Antibody Helps Repair MS Nerve Damage
4. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
5. ThromboGenics Begins Preclinical Development of Anti-VPAC Antibody for Thrombocytopenia
6. Antibody responses in patients with Lyme arthritis
7. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
8. Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product
9. Antibody Engineering Company f-star Appoints Three Pioneers in Antibody Engineering and Development to its Newly Established Scientific Advisory Board
10. EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
11. Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... While it’s often important to take certain medications during ... Austin, Texas, has identified a solution. , She developed a prototype for MOTION LIGHT-UP ... such, it eliminates the need to turn on a light when taking medication during ...
(Date:10/13/2017)... ... 13, 2017 , ... Lori R. Somekh, founder of the Law Office ... of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office ... forum to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... Milford, NJ (PRWEB) , ... October 13, 2017 , ... ... weekend at scenic Alexandria Park in Milford, NJ. This free event, sponsored by ... and physical activity. The fun run is geared towards children of all ages; ...
(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/19/2017)... Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, ... tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , PhD, ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
Breaking Medicine Technology: